COVID-19 vaccine safety report – 02-11-23 – Therapeutic Goods Administration (TGA)

The most frequently reported side effects suspected to be associated with the vaccines include headache, muscle pain, fever, fatigue and nausea. Skin reactions at the site of the injection are also common and can include pain, swelling, redness and an itchy rash. These are recognised side effects of vaccination and are usually transient and mild.

The most up-to-date vaccine recommendations for children are available from ATAGI.

The TGA is closely monitoring adverse event reports in people aged under 18 years. Reporting rates of adverse events following COVID-19 vaccination, including those for children and adolescents, are very stable. More detail on vaccine safety in children and adolescents following vaccination is available in the safety report published on 15 December 2022.

The most up-to-date vaccine recommendations for booster doses are available from ATAGI.

The TGA continues to monitor the safety of booster vaccine doses in adults. A booster dose is an additional vaccine dose given after the primary vaccine course. In people who have recently had COVID-19, a 6-month interval is recommended before having their next scheduled dose.

Reporting rates of adverse events following booster doses are very stable. A small number of myocarditis and pericarditis cases have been reported for booster doses. We are closely monitoring these events. So far, reports of myocarditis after a booster dose are very rare, occurring in less than 1 in every 100,000 doses administered.

Information on vaccine safety following booster doses is available in the safety report published on 15 December 2022.

Vaccines can lead to death in extremely rare instances. However, most deaths that occur after vaccination are not caused by the vaccine. In large populations in which a new vaccine is given, there are people with underlying diseases who may die from these diseases. When a vaccine is given in that same population, the link between the vaccine and death is usually coincidental not caused by the vaccine. These deaths are carefully reviewed to assess whether vaccines could be the cause and for the vast majority that is not the case.

The TGA closely reviews all deaths reported in the days and weeks after COVID-19 vaccination. Read more about this process in a previous report. Since the beginning of the vaccine rollout to 29 October 2023, almost 69 million doses of COVID-19 vaccines have been given in Australia. The TGA has identified 14 reports where the cause of death was linked to vaccination from 1,004 reports received and reviewed.There have been no new vaccine-related deaths identified since 2022.

The 14 deaths likely to be related to vaccination occurred in people aged 21-81 years old. There have been no deaths in children or adolescents determined to be linked to COVID-19 vaccination. More detail on these deaths is available in the safety report published on 15December 2022.

If we identify a new death likely to be related to vaccination, we will publish this information promptly, as we have for all other cases since the start of the vaccine roll-out.

It is important when looking for information about COVID-19 vaccines to consider whether the source of the information is credible and trustworthy. Websites such as COVID vaccines is it true? and COVID-19 vaccines: Frequently asked questions help to debunk false claims and misleading rumours.

The original Comirnaty (Pfizer) vaccine is provisionally approved for adults and children aged 5 years and over. Two bivalent vaccines are available from Pfizer for use as booster doses Comirnaty Original/Omicron BA.1 and Comirnaty Original/Omicron BA.4-5.

To 29 October 2023, more than 44 million doses have been administered in Australia, as well as almost 2.9 million doses of the bivalent booster vaccines.

The TGA continues to monitor reports of myocarditis (inflammation of the heart) and/or pericarditis (inflammation of the membrane around the heart) associated with mRNA vaccines.

Rates of these side effects are very stable. Myocarditis is reported in around 1-2 in every 100,000 people who receive Comirnaty (Pfizer). More detail on our analysis of myocarditis and pericarditis following vaccination is available in a previous vaccine safety report.

Go to the Comirnaty (Pfizer) information page to find out more about these vaccines.

Up-to-date information for Comirnaty (Pfizer), including details of potential side effects, can be found in the Consumer Medicine Information (for consumers) and Product Information (for health professionals).

The Spikevax vaccine is fully approved for adults and children aged 6 years and over. Two bivalent vaccines are available from Moderna for use as booster doses Spikevax Original/Omicron BA.1 and Spikevax Original/Omicron BA.4-5 vaccine.

To 29 October 2023, more than 5million doses have been administered in Australia, as well as almost 1.4 million doses of the bivalent booster vaccines.

The TGA continues to monitor reports of myocarditis (inflammation of the heart) and/or pericarditis (inflammation of the membrane around the heart) associated with mRNA vaccines.

Rates of these side effects are very stable. Myocarditis is reported in around 2 in every 100,000 of those who receive Spikevax (Moderna). More detail on our analysis of myocarditis and pericarditis following vaccination is available in a previous vaccine safety report.

Go to the Spikevax (Moderna) information page to find out more about these vaccines.

Up-to-date information for Spikevax (Moderna), including details of potential side effects, can be found in the Consumer Medicine Information (for consumers) and Product Information (for health professionals).

TheNuvaxovid (Novavax) vaccine is provisionally approved for adults. To 29 October 2023, almost 268,000 doses of Nuvaxovid (Novavax) have been administered in Australia.

The TGA continues to monitor reports of myocarditis (inflammation of the heart) and pericarditis (inflammation of the membrane around the heart) following vaccination.

Rates of these side effects are very stable. Myocarditis is reported in around 4 in every 100,000 people who receive the Nuvaxovid (Novavax) vaccine. More detail on our analysis of myocarditis and pericarditis following vaccination with Nuvaxovid (Novavax) is available in a previous vaccine safety report.

Go to the Nuvaxovid (Novavax) information page to find out more about this vaccine.

More information for Nuvaxovid (Novavax), including details about its ingredients and potential side effects, can be found in the Consumer Medicine Information (for consumers) and Product Information (for health professionals).

The Vaxzevria (AstraZeneca) vaccine is no longer available for use in Australia. Almost 14million doses of Vaxzevria (AstraZeneca) were administered when it was in use.

Go to the Vaxzevria (AstraZeneca) information page to find out more about this vaccine.

More general information for Vaxzevria (AstraZeneca), including details of potential side effects can be found in the Consumer Medicine Information (for consumers) and Product Information (for health professionals).

Watch this video to find out how the TGA monitors and reports the safety of COVID-19 vaccines

COVID-19 vaccines: Frequently asked questions 26 July 2023

COVID vaccines is it true? 8 May 2023

Latest clinical recommendations for COVID-19 vaccines in Australia 5 October 2023

Latest advice on COVID-19 vaccination for pregnant and breastfeeding women

TGA COVID-19 vaccines hub

Australian Government Department of Health COVID-19 vaccines hub

COVID vaccine information in your language

Database of Adverse Event Notifications (DAEN)

AusVaxSafety a national survey on COVID-19 vaccine safety

See the original post here:

COVID-19 vaccine safety report - 02-11-23 - Therapeutic Goods Administration (TGA)